SCHEMBL7222402

SCHEMBL7222402

Cc1cc(NS(=O)(=O)c2ccc3ccccc3c2)cc(C)c1S(=O)(=O)C[N+](=O)[O-]

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.60
PKLR P30613 1/20 0.60
KMT2A Q03164 6/20 0.54
MEN1 O00255 5/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
MAPT P10636 2/20 0.54
HTT P42858 2/20 0.54
ATM Q13315 1/20 0.52
LMNA P02545 3/20 0.51
ALDH1A1 P00352 2/20 0.51
GAA P10253 1/20 0.51
PGR P06401 1/20 0.47
HSD11B1 P28845 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
AKT1 P31749 1/20 0.46
HDAC3 O15379 1/20 0.45
HDAC4 P56524 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC2 Q92769 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7223946 0.88 CYTH2 (0.46) PKMPKLRKMT2AMEN1MAPT
SCHEMBL7221678 0.88 CYTH2 (0.56) PKMKMT2AMEN1SMN1; SMN2MAPT
SCHEMBL7230113 0.84 CYTH2 (0.49) PKMKMT2AMEN1MAPTHTT
SCHEMBL7224301 0.84 KMT2A (0.50) PKMKMT2AMEN1SMN1; SMN2MAPT
SCHEMBL7225029 0.84 ALDH1A1 (0.50) PKMKMT2AMEN1MAPTHTT
SCHEMBL7228550 0.83 FFAR4 (0.53) PKMKMT2AMEN1SMN1; SMN2HTT
SCHEMBL7221797 0.83 CYTH2 (0.43) PKMKMT2AMEN1MAPTHTT
SCHEMBL7224282 0.82 PGR (0.44) PKMKMT2ASMN1; SMN2MAPTLMNA
SCHEMBL7222797 0.82 HSD17B2 (0.52) PKMSMN1; SMN2MAPTALDH1A1PGR
SCHEMBL7230408 0.82 PKM (0.59) PKMSMN1; SMN2MAPTLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030203966-A1 Nitromethylthiobenzene derivatives as aldose reductase inhihibitors COLLONGES FRANCOIS (FR) 2003-10-30 US disclosed
US-6509499-B1 Nervous system disorders, vision defects, diabetic retinopathy, neuropathic pain and kidney disorder treatment MERCK PATENTGESELLSCHAFT MIT (DE) 2003-01-21 US disclosed
EP-0946503-B1 NITROMETHYLTHIOBENZENE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE MERCK PATENT GMBH (DE) 2002-03-27 EP disclosed
EP-0946503-A1 NITROMETHYLTHIOBENZENE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE MERCK PATENT GmbH (DE) 1999-10-06 EP disclosed
WO-1998028265-A1 NITROMETHYLTHIOBENZENE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE MERCK PATENT GMBH (DE) 1998-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203966-A1 Nitromethylthiobenzene derivatives as aldose reductase inhihibitors AKR1B1, ALDOA, AKR1C1 PKM 621/4885PKLR 601/4885KMT2A 4070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.